A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Invest New Drugs
; 36(5): 886-894, 2018 10.
Article
in En
| MEDLINE
| ID: mdl-29766337
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Proto-Oncogene Proteins c-met
/
Protein Kinase Inhibitors
/
Neoplasms
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2018
Type:
Article